TP53 and cancer: Based on gene mutation patterns and genomic changes, the two cell lines are representative of luminal like FGFR3-driven cancer (RT112), and of the basal-like TP53/RB tumor suppressor-driven cancer (5736), often used as models of non-aggressive and aggressive BCs, respectively [41,42].